Anca Vasculitis - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 59 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

nca Vasculitis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Anca Vasculitis - Pipeline Review, H1 2015’, provides an overview of the Anca Vasculitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anca Vasculitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anca Vasculitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anca Vasculitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Anca Vasculitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Anca Vasculitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anca Vasculitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anca Vasculitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anca Vasculitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Anca Vasculitis Overview 6
Therapeutics Development 7
Pipeline Products for Anca Vasculitis - Overview 7
Pipeline Products for Anca Vasculitis - Comparative Analysis 8
Anca Vasculitis - Therapeutics under Development by Companies 9
Anca Vasculitis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Anca Vasculitis - Products under Development by Companies 13
Anca Vasculitis - Companies Involved in Therapeutics Development 14
Anthera Pharmaceuticals‚ Inc. 14
ChemoCentryx, Inc. 15
GlaxoSmithKline plc 16
Kineta, Inc. 17
Anca Vasculitis - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
belimumab - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
blisibimod - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
CCX-1378 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
CCX-1641 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
CCX-168 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
dalazatide - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
mepolizumab - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Anca Vasculitis - Recent Pipeline Updates 42
Anca Vasculitis - Product Development Milestones 53
Featured News & Press Releases 53
Nov 17, 2014: ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit In Non-Renal ANCA Vasculitis Disease Activity, In Addition To Previously Shown Kidney Disease Improvements 53
Jun 02, 2014: ChemoCentryx's Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit in ANCA-Associated Vasculitis Based on Birmingham Vasculitis Activity Score and Renal Disease Measurements 54
Dec 03, 2013: ChemoCentryx Announces Positive Top-Line CCX168 Phase II Data in ANCA-Associated Renal Vasculitis 55
Nov 10, 2010: ChemoCentryx Presents Positive Phase I Results For CCX168 At Annual American College Of Rheumatology Meeting 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59

List of Tables

Number of Products under Development for Anca Vasculitis, H1 2015 7
Number of Products under Development for Anca Vasculitis - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Anca Vasculitis - Pipeline by Anthera Pharmaceuticals‚ Inc., H1 2015 14
Anca Vasculitis - Pipeline by ChemoCentryx, Inc., H1 2015 15
Anca Vasculitis - Pipeline by GlaxoSmithKline plc, H1 2015 16
Anca Vasculitis - Pipeline by Kineta, Inc., H1 2015 17
Assessment by Monotherapy Products, H1 2015 18
Number of Products by Stage and Target, H1 2015 20
Number of Products by Stage and Mechanism of Action, H1 2015 22
Number of Products by Stage and Route of Administration, H1 2015 24
Number of Products by Stage and Molecule Type, H1 2015 26
Anca Vasculitis Therapeutics - Recent Pipeline Updates, H1 2015 42